Health Stocks News
@health_stocks
Followers
2,642
Following
250
Media
3
Statuses
33,990
Real-Time News, Market Data, Stock Quotes, Insider Trades, FDA Calendar, News Alerts, Stock Lists, Stock Screener, Heat Map @
United States
Joined January 2019
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#ไฟไหม้รถบัส
• 749641 Tweets
GLORIOUS REBECCA IN PFW25
• 649537 Tweets
JENNIE FOR CHANEL
• 250139 Tweets
Nigeria
• 222647 Tweets
Happy New Month
• 129030 Tweets
Iniesta
• 32718 Tweets
世界4位
• 30075 Tweets
メガネの日
• 30019 Tweets
레이예스
• 26877 Tweets
#格付けチェック
• 25017 Tweets
Fate/Zero
• 22420 Tweets
夕刊フジ
• 17229 Tweets
対象作品
• 17114 Tweets
集英社秋マンガチャ開催
• 15143 Tweets
#ドレミファドン
• 13038 Tweets
日本酒の日
• 12667 Tweets
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property $NWBO
0
10
52
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy $OCGN
0
14
45
Cassava Sciences Appoints Three New Members to its Board of Directors $SAVA
1
7
45
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication $OCGN
1
11
43
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy $OCGN
0
14
38
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop $OCGN
0
15
37
Ocugen to Present at 2024 BIO CEO & Investor Conference $OCGN
1
14
37
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 $OCGN
0
16
36
The Iowa Clinic Signs Multi-Year Agreement with Counterpart Health to Deploy Proven AI Technology to Hundreds of Providers Across the Midwest $CLOV
4
8
36
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting $OCGN
1
16
34
T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs - Health Stocks Hub $TTOO
1
10
32
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication $OCGN
2
16
31
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification $NWBO
0
6
29
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board - Health Stocks Hub $NWBO
0
5
28
Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold $NNOX
1
5
28
Ocugen Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication $OCGN
0
11
26
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer - Health Stocks Hub $XFOR
1
2
26
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics - Health Stocks Hub $RDGL
3
8
24
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease $OCGN
0
15
24
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy $OCGN
0
9
23
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease $OCGN
0
9
23
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy $OCGN
1
11
21
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials $SAVA
0
2
22
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa $OCGN
0
9
22
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility $XFOR
1
2
22
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 $OCGN
0
8
20
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy $OCGN
0
8
20
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities $NWBO
0
4
20
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults - Health Stocks Hub $NBIX
0
3
20
Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application - Health Stocks Hub $NWBO
0
5
19
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference $TTOO
2
6
18
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID $VIRI
0
5
17
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication $OCGN
0
7
17
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results - Health Stocks Hub $OCGN
0
4
16
T2 Biosystems Reports Granting of Inducement Award $TTOO
1
5
14
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference $SAVA
2
6
15
T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing $TTOO
0
4
13
Ocugen Provides Business Update with Second Quarter 2024 Financial Results $OCGN
0
7
13
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia - Health Stocks Hub $VIRI
1
4
14
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041 $URGN
0
3
13
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease $LLY
4
3
12
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia $IXHL
0
5
13
Novo Integrated Sciences Advised Receipt of Proceeds of RC Consulting Promissory Note Expected in 3-5 Business Days $NVOS
0
5
12
Innovative Data Featuring Nanox AI Cardiac Solution Showcased at SCCT 2024 $NNOX
0
3
13
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert $MYNZ
3
0
3
Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks $LLY
1
1
13
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy $OCGN
0
10
12
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST $OCGN
0
5
12
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care $JAGX
0
4
12
Ocugen to Present at BIO International Convention 2024 $OCGN
1
5
11
T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii $TTOO
0
1
10
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy $ARDX
1
2
11
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board $OCGN
1
4
12
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation $MRTX
2
1
9
Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver $NNOX
0
0
11
Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium $NNOX
0
1
11
Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update $NNOX
0
1
11
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials $RDGL
0
7
11
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results $NVTA
0
1
11
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label $LQDA
0
6
11
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor $ARDX
1
6
11
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution $SAVA
0
3
11
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel $TTOO
0
1
10
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference $PCSA
0
5
9
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population $AGEN
0
4
9
Nanox Announces Strategic Manufacturing Agreement with Varex Imaging Corporation to Advance the Nanox.ARC Medical Imaging System $NNOX
0
0
10
Clover Health to Present at Bank of America 2023 Healthcare Conference on May 11, 2023 $CLOV
2
4
9
Expands Footprint Through New Global Partnership with Ferrum Health $NNOX
0
1
9
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates $JAGX
0
3
10
CMS Improves Star Ratings to 3.5 Stars for Clover Health PPO Medicare Advantage Plans for 2025 Payment Year $CLOV
0
0
9
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement $TTOO
2
1
9
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial $ATOS
0
1
9
Tenapanor for Hyperphosphatemia Approved in Japan $ARDX
1
2
9
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use $ESPR
2
3
9
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Health Stocks Hub $DAWN
0
2
9
Ocugen Provides Business Update with First Quarter 2024 Financial Results $OCGN
0
5
8
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above $SRPT
0
1
9
Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval $NVOS
1
2
9
T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023 $TTOO
1
3
9
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs $JAGX
0
3
8
Clover Health Reports Strong First Quarter 2024 Financial Results; Improves Guidance to Target Full-Year 2024 Adjusted EBITDA Profitability $CLOV
0
1
8
Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America $MGRX
0
6
8
Novo Integrated Sciences Provides Update on Certain Current Actions and Events - Health Stocks Hub $NVOS
0
4
8
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize $TTOO
0
6
6
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis $GLTO
3
3
7
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases $CRVS
0
3
8
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental' $BIOL
0
1
8
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation $RDGL
0
5
8
Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA $RDGL
3
0
8
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials $OCGN
0
5
8
Ocugen Announces Proposed Public Offering of Common Stock $OCGN
1
3
8
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration $MGRX
0
3
7
PCP Use of Clover Health Assistant Correlated with Increased Medication Fills for Patients who Were Previously Non-Adherent $CLOV
1
2
7
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting $AQST
0
0
7
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab $CLDX
0
2
7
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting $XAIR
0
4
7
Novo Integrated Sciences’ Board of Directors Approves $5 Million Stock Repurchase Program $NVOS
0
3
7
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital $ADAP
0
6
7
Clarion Clinics Open for Psychedelic-Assisted Treatments $IXHL
1
1
7
Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance $CLOV
0
1
6